porcin
reproduct
respiratori
syndrom
swine
influenza
acut
highli
contagi
swine
diseas
diseas
pose
sever
threat
swine
industri
caus
heavi
econom
loss
worldwid
studi
develop
chimer
viruslik
particl
vlp
vaccin
candid
porcin
reproduct
respiratori
syndrom
viru
prrsv
influenza
viru
investig
immunogen
mice
ha
protein
influenza
viru
prrsv
protein
fuse
cytoplasm
transmembran
domain
na
protein
incorpor
chimer
vlp
analysi
immun
respons
show
chimer
vlp
elicit
serum
antibodi
specif
prrsv
ha
protein
stimul
cellular
immun
respons
compar
respons
equival
amount
inactiv
virus
taken
togeth
result
suggest
chimer
vlp
vaccin
repres
potenti
strategi
develop
safe
effect
vaccin
control
prrsv
influenza
viru
c
xue
w
wang
contribut
equal
work
influenza
viru
segment
negativestrand
rna
viru
belong
famili
orthomyxovirida
among
larg
varieti
speci
influenza
virus
infect
natur
swine
influenza
viru
siv
caus
acut
highli
contagi
respiratori
diseas
swine
epitheli
cell
swine
respiratori
tract
receptor
avian
mammalian
influenza
virus
therefor
pig
might
serv
mix
vessel
gener
new
reassort
strain
pandem
capac
three
predomin
subtyp
preval
differ
countri
porcin
reproduct
respiratori
syndrom
viru
prrsv
caus
agent
porcin
reproduct
respiratori
syndrom
prr
member
famili
arterivirida
order
nidoviral
viru
caus
one
econom
import
infecti
diseas
swine
industri
worldwid
prr
predominantli
character
reproduct
failur
breed
swine
prewean
mortal
respiratori
disord
pig
age
vaccin
effect
way
reduc
incid
diseas
result
influenza
viru
prrsv
infect
compar
convent
vaccin
kill
vaccin
attenu
vaccin
viruslik
particl
vlp
demonstr
promis
altern
candid
new
form
vaccin
candid
noninfecti
natur
vlp
lack
viral
genom
materi
attract
safeti
featur
may
suitabl
varieti
virus
b
cellmedi
antibodi
specif
tcellmedi
cellular
respons
elicit
vlp
vlp
mimic
overal
structur
virion
also
present
conform
epitop
surfac
protein
readili
recogn
process
antigenpres
cell
protect
effect
vlp
demonstr
clinic
preclin
trial
import
advanc
would
develop
new
vlp
enhanc
breadth
immun
could
potenti
use
prevent
infect
prrsv
siv
previou
studi
express
protein
prrsv
surfac
chimer
vlp
elicit
humor
cellular
immun
respons
neutral
antibodi
respons
prrsv
base
platform
hope
gener
chimer
vlp
protect
prr
influenza
studi
chose
influenza
viru
basi
vlp
product
expect
fusion
protein
combin
ha
effect
form
chimer
vlp
next
demonstr
chimer
vlp
induc
potent
immun
respons
prrsv
siv
balbc
mice
model
henc
result
suggest
chimer
vlp
vaccin
new
vaccin
candid
protect
prr
influenza
spodoptera
frugiperda
cell
maintain
serumfre
medium
gibco
spinner
flask
speed
rpm
prrsv
strain
propag
cell
maintain
dulbecco
modifi
eagl
medium
dmem
gibco
supplement
penicillinstreptomycin
fetal
calf
serum
co
strain
influenza
viru
propag
mdck
cell
condit
cell
maintain
dmem
supplement
penicillinstreptomycin
fetal
calf
serum
co
ha
na
gene
influenza
viru
access
number
gene
prrsv
access
number
fusion
gene
insert
pfastbacdu
vector
describ
previous
gene
clone
vector
pfastbacdu
control
differ
promot
plasmid
confirm
dna
sequenc
ensur
addit
chang
introduc
pcr
recombin
baculovirus
rbv
deriv
transfer
plasmid
pfastbacdualha
use
bactobac
baculoviru
express
system
virus
harvest
supernat
subject
three
round
plaqu
purif
cell
coinfect
rbv
express
ha
differ
ratio
incub
h
cell
show
high
degre
cytopatholog
cultur
supernat
collect
centrifug
min
analyz
western
blot
express
influenza
viru
protein
ha
detect
mous
polyclon
sera
influenza
viru
fusion
protein
detect
mous
polyclon
sera
prrsv
horseradish
peroxidas
hrp
conjug
goat
antimous
igg
polyclon
antibodi
use
secondari
antibodi
ptglab
usa
produc
vlp
contain
ha
cell
coinfect
rbv
express
ha
protein
ratio
incub
h
vlp
harvest
purifi
use
wv
discontinu
sucros
step
densiti
gradient
ultracentrifug
min
fraction
collect
analyz
presenc
ha
protein
western
blot
content
chimer
vlp
quantifi
grayscal
scan
sdspage
gel
hemagglutin
activ
vlp
determin
use
chicken
red
blood
cell
electron
microscopi
sucrosegradientpurifi
vlp
appli
carbonco
formvar
grid
min
grid
immedi
stain
phosphotungst
acid
ph
stain
vlp
observ
transmiss
electron
microscopi
jeolltd
japan
four
group
sixweekold
femal
inbr
spf
balbc
mice
n
hous
microisol
unit
allow
free
access
food
water
mice
immun
intramuscularli
im
lg
chimer
vlp
contain
lg
protein
complet
freund
adjuv
cfa
primari
immun
week
incomplet
freund
adjuv
ifa
subsequ
boost
week
posit
control
group
immun
im
formalininactiv
prrsv
amount
equal
chimer
vlp
formalininactiv
influenza
viru
amount
ha
equal
chimer
vlp
pb
inject
neg
control
blood
sampl
collect
immun
day
primari
immun
experi
carri
accord
ethic
guidelin
anim
protect
china
approv
sun
yatsen
univers
anim
ethic
committe
procedur
perform
anesthesia
effort
made
minim
suffer
briefli
plate
coat
antigen
concentr
lgml
coat
buffer
sodium
carbon
ph
overnight
antigen
use
target
extract
prepar
cell
transfect
pfastbacdualha
express
ha
protein
protein
plate
block
pb
contain
bsa
h
incub
serial
dilut
sampl
h
follow
thorough
wash
pb
contain
sampl
incub
horseradish
peroxidas
hrp
label
goat
antimous
igg
stock
concentr
mgml
dilut
pb
contain
bsa
h
unbound
antibodi
remov
well
thoroughli
wash
substrat
tmb
sangon
china
citratephosph
buffer
ph
contain
h
use
color
develop
reaction
termin
absorb
determin
nm
use
spectrophotomet
biotek
usa
lymphocyt
isol
spleen
cytokin
elispot
assay
briefli
spleen
care
rins
steril
pb
deplet
erythrocyt
treatment
ammonium
chlorid
ph
follow
thorough
wash
pb
cell
isol
spleen
use
mous
lymphocyt
separ
medium
dakew
china
collect
cell
centrifug
min
room
temperatur
resuspend
lymphospot
serumfre
medium
rodent
dakew
cell
viabil
determin
stain
trypan
blue
sigma
precoat
antimifnc
lgml
coat
buffer
bdpharmingen
plate
millipor
incub
ml
lymphospot
serumfre
medium
rodent
min
incub
splenocyt
isol
vaccin
mice
well
splenocyt
stimul
protein
ha
protein
concentr
lgml
addit
well
cell
stimul
pma
ngml
ionomycin
ngml
mock
stimul
plate
incub
h
co
plate
thoroughli
wash
pb
contain
incub
biotinyl
antimifnc
h
plate
wash
incub
streptavidin
conjug
alkalin
phosphatas
h
follow
extens
wash
antibodycytokineantibodi
complex
incub
stabl
bcipnbt
chromagen
min
plate
rins
ddh
air
dri
h
spot
count
use
immunospot
elispot
reader
biosi
germani
sera
complementinactiv
min
test
serial
dilut
twofold
dmem
without
serum
mix
prrsv
mixtur
ad
prewash
cell
grow
tissu
cultur
dish
incub
co
h
cell
examin
observ
appear
cytopath
effect
cpe
neutral
titer
express
reciproc
highest
serum
dilut
neutral
tcid
prrsv
well
hemagglutin
inhibit
hi
assay
use
assess
abil
function
haspecif
antibodi
inhibit
agglutin
chicken
erythrocyt
briefli
sera
treat
receptordestroy
enzym
serial
dilut
twofold
vbottom
microtit
plate
equal
volum
four
adjust
hemagglutin
unit
inactiv
strain
influenza
viru
ad
well
plate
cover
incub
room
temperatur
min
follow
addit
red
blood
cell
rbc
pb
hi
titer
determin
reciproc
dilut
last
row
contain
nonagglutin
rbc
neg
serum
control
includ
plate
geometr
mean
hi
titer
standard
error
calcul
within
group
paramet
record
individu
mice
within
group
statist
comparison
data
group
carri
use
analysi
varianc
test
anova
statist
analys
perform
use
student
twotail
test
equal
varianc
pvalu
less
p
consid
statist
signific
cell
coinfect
recombin
baculovirus
express
ha
protein
differ
ratio
cultur
supernat
harvest
analyz
western
blot
fig
b
differ
ratio
led
differ
level
protein
express
result
suggest
infect
rbv
express
ha
protein
ratio
optim
chimer
vlp
product
chimer
vlp
produc
releas
cultur
supernat
insect
cell
coinfect
rbv
express
ha
describ
vlp
purifi
sucros
gradient
ultracentrifug
character
western
blot
fraction
contain
vlp
could
observ
sucros
densiti
incorpor
ha
protein
vlp
confirm
fig
b
electron
microscop
examin
neg
stain
sampl
reveal
presenc
vlp
diamet
approxim
nm
fig
ha
titer
immunogen
chimer
vlp
evalu
mous
immun
trial
presenc
freund
adjuv
ha
protein
use
antigen
influenza
viru
antibodi
detect
mice
vaccin
vlp
inactiv
viru
vaccin
formul
elicit
serum
antiha
protein
antibodi
respons
follow
first
vaccin
boost
second
vaccin
fig
group
vlp
infect
intramuscularli
posit
control
group
show
consider
igg
titer
significantli
higher
neg
control
group
p
fig
differ
igg
titer
vlp
group
posit
control
statist
signific
p
importantli
chimer
vlp
induc
signific
igg
titer
prrsv
protein
compar
neg
control
group
p
fig
differ
igg
titer
vlp
group
posit
control
group
statist
signific
p
immun
respons
ha
protein
data
show
fusion
ectodomain
na
hinder
function
antigen
meanwhil
product
immun
respons
ha
protein
indic
chimer
vlp
administ
via
intramuscular
rout
could
effect
induc
respons
two
differ
antigen
compar
induc
posit
control
vaccin
number
ifnc
cytokinesecret
cell
determin
use
specif
sensit
elispot
assay
spleen
harvest
vaccin
mice
lymphocyt
isol
last
immun
cell
stimul
either
protein
ha
protein
data
show
signific
number
ifncand
cell
induc
chimer
vlp
group
posit
control
group
neg
control
mice
p
whether
protein
fig
b
ha
protein
fig
use
stimulu
notabl
mice
immun
chimer
vlp
elicit
cellular
immun
respons
might
help
suppress
viral
replic
reduc
viral
infect
prrsv
influenza
viru
neutral
activ
play
import
role
first
line
defens
prrsv
infect
clearanc
prrsv
like
confer
protect
immun
perform
neutral
assay
shown
fig
prrsvspecif
neutral
antibodi
detect
day
primari
immun
elev
day
increas
highest
level
day
furthermor
neutral
antibodi
prrsv
detect
pb
group
hi
result
demonstr
singl
intramuscular
immun
vlp
vaccin
presenc
adjuv
elicit
rel
modest
hi
titer
inactiv
influenza
viru
strain
two
booster
immun
induc
high
hi
titer
indic
vlp
strongli
immunogen
fig
prrsv
siv
coinfect
pig
certain
condit
two
agent
associ
mycoplasm
hyopneumonia
mhyo
pasturella
multocida
porcin
circoviru
type
report
constitut
porcin
respiratori
diseas
complex
prdc
previou
studi
indic
siv
prrsv
primari
etiolog
agent
associ
respiratori
diseas
pig
presenc
prrsv
vaccin
reduc
efficaci
vaccin
neg
impact
either
system
local
antibodi
respons
either
siv
vaccin
challeng
previous
prepar
chimer
vlp
compos
protein
influenza
viru
fusion
protein
denot
na
contain
cytoplasm
transmembran
domain
viru
na
protein
prrsv
protein
demonstr
immun
balbc
mice
chimer
vlp
could
stimul
robust
immun
respons
base
result
import
advanc
would
develop
new
vaccin
could
use
prevent
coinfect
prrsv
siv
fig
serum
sampl
collect
day
primari
immun
determin
neutral
antibodi
titer
data
repres
mean
sd
eight
mice
differ
neutral
antibodi
titer
experiment
group
statist
signific
p
fig
hemagglutinationinhibit
hi
titer
serum
sampl
collect
day
primari
immun
mice
per
group
vaccin
chimer
vlp
inactiv
viru
pb
hi
respons
assess
compar
virus
differ
hi
titer
experiment
group
statist
signific
p
influenza
viru
virion
surround
lipid
membran
contain
two
major
glycoprotein
ha
na
ha
protein
abund
glycoprotein
respons
attach
viru
termin
sialic
acid
residu
host
cell
receptor
mediat
fusion
viral
cellular
membran
influenza
vlp
could
obtain
express
four
viral
protein
ha
na
three
viral
protein
ha
na
two
viral
protein
ha
even
ha
alon
recent
demonstr
influenza
vlp
made
fusion
protein
therefor
influenza
vlp
chosen
platform
prrsv
protein
express
previou
report
show
base
assembl
newcastl
diseas
nd
vlp
possibl
develop
chimer
vlp
contain
respiratori
syncyti
viru
rsv
g
protein
use
nd
vlp
platform
well
nd
vlp
contain
rsv
g
f
protein
studi
show
ha
protein
could
assembl
form
chimer
vlp
compar
previou
result
ha
influenc
format
chimer
vlp
size
morpholog
chimer
vlp
similar
natur
influenza
viru
ha
titer
chimer
vlp
indic
ha
structur
function
incorpor
particl
result
suggest
might
feasibl
gener
chimer
influenza
vlp
way
immunogen
chimer
vlp
mice
demonstr
effect
induc
immun
data
show
inactiv
viru
chimer
vlp
vaccin
gener
compar
amount
prrsvspecif
antibodi
measur
elisa
splenocyt
prolifer
vigor
produc
ifncand
respons
stimul
ha
antigen
follow
three
immun
vlp
vaccin
induc
hi
antibodi
homolog
influenza
strain
mice
find
provid
evid
chimer
vlp
induc
protect
immun
influenza
viru
similarli
kill
viru
meanwhil
measur
neutral
antibodi
titer
significantli
elev
neutral
antibodi
prrsv
achiev
vlp
group
well
inactiv
prrsv
p
result
demonstr
prrsv
protein
coincorpor
influenza
na
form
chimer
vlp
ha
could
identifi
transfer
effici
prrsv
antigen
report
recent
vlp
hepat
b
viru
core
protein
contain
five
mimotop
infecti
bursal
diseas
viru
ibdv
protect
chicken
ibdv
use
genet
engin
noroviru
vlp
incorpor
relev
epitop
multipl
strain
multival
vaccin
formul
increas
breadth
immun
respons
divers
variant
within
genotyp
summari
found
chimer
vlp
induc
antibodi
two
diseas
time
contrast
chimer
vlp
previou
studi
data
present
studi
show
intramuscular
immun
mice
chimer
vlp
induc
system
immun
respons
includ
humor
cellular
immun
compon
similar
research
chimer
sarscov
glycoprotein
influenza
effici
form
vlp
protect
mice
challeng
sarscov
experiment
tripleha
vlp
contain
ha
protein
deriv
virus
immunogen
protect
ferret
challeng
three
potenti
pandem
virus
addit
vlp
contain
ha
subtyp
deriv
season
type
b
influenza
virus
protect
ferret
three
season
influenza
virus
therefor
clear
chimer
vlp
effect
kill
virus
result
show
immun
respons
chimer
vlp
similar
vlp
compos
na
protein
less
anim
need
handl
deliv
vaccin
better
presenc
multipl
viru
target
singl
vaccin
new
advantag
chimer
vlp
vaccin
vaccin
could
also
reduc
burden
vaccin
product
administr
comparison
regular
vaccin
basic
step
studi
protect
efficaci
chimer
vlp
swine
model
need
carri
summari
studi
provid
proof
concept
chimer
vlp
vaccin
gener
antiprrsv
immun
respons
chimer
vlp
could
serv
promis
vaccin
strategi
control
prr
influenza
swine
although
respons
immun
chimer
vlp
effect
respons
inactiv
virus
fact
chimer
vlp
infecti
lack
viral
genom
materi
mean
could
provid
safer
method
prevent
viral
infect
furthermor
product
chimer
vlp
faster
present
lower
risk
rel
tradit
method
thu
approach
greater
potenti
vaccin
develop
